Evaluation of the association between patent ductus arteriosus approach and neurodevelopment in extremely preterm infants.
J Perinatol
; 44(3): 388-395, 2024 Mar.
Article
in En
| MEDLINE
| ID: mdl-38278962
ABSTRACT
OBJECTIVE:
Assess if unit-level PDA management correlates with neurodevelopmental impairment (NDI) at 18-24 months corrected postnatal age (CPA) in extremely preterm infants. STUDYDESIGN:
Retrospective analysis of infants born at <29 weeks (2014-2017) across two units having distinct PDA strategies. Site 1 utilized an echocardiography-based treatment strategy aiming for accelerated closure (control). Site 2 followed a conservative approach. PRIMARY ENDPOINT NDI, characterized by cerebral palsy, any Bayley-III composite score <85, sensorineural/mixed hearing loss, or at least unilateral visual impairment.RESULTS:
377 infants were evaluated. PDA treatment rates remained unchanged in Site 1 but eventually reached 0% in Site 2. Comparable rates of any/significant NDI were seen across both sites (any NDI 38% vs 36%; significant NDI 13% vs 10% for Site 1 and 2, respectively). After adjustments, NDI rates remained similar.CONCLUSION:
PDA management strategies in extremely preterm newborns showed no significant impact on neurodevelopment outcomes at 18-24 months CPA.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Persistent Fetal Circulation Syndrome
/
Ductus Arteriosus, Patent
Type of study:
Risk_factors_studies
Limits:
Humans
/
Infant
/
Newborn
Language:
En
Journal:
J Perinatol
Year:
2024
Document type:
Article